WallStreetZenWallStreetZen

NASDAQ: AKTX
Akari Therapeutics PLC Stock

$3.62+0.13 (+3.72%)
Updated Sep 22, 2023
AKTX Price
$3.62
Fair Value Price
$3.83
Market Cap
$26.95M
52 Week Low
$2.81
52 Week High
$13.40
P/E
N/A
P/B
15.05x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$17.75M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
6.72
Operating Cash Flow
-$22M
Beta
0.59
Next Earnings
Sep 27, 2023
Ex-Dividend
N/A
Next Dividend
N/A

AKTX Overview

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.

Zen Score

Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AKTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

AKTX ($3.62) is undervalued by 5.54% relative to our estimate of its Fair Value price of $3.83 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
AKTX ($3.62) is not significantly undervalued (5.54%) relative to our estimate of its Fair Value price of $3.83 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
AKTX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more AKTX due diligence checks available for Premium users.

Be the first to know about important AKTX news, forecast changes, insider trades & much more!

AKTX News

Valuation

AKTX fair value

Fair Value of AKTX stock based on Discounted Cash Flow (DCF)
Price
$3.62
Fair Value
$3.83
Undervalued by
5.54%
AKTX ($3.62) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AKTX ($3.62) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation

AKTX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
0x
Industry
12.89x
Market
14.52x

AKTX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
15.05x
Industry
5.11x
AKTX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

AKTX's financial health

Profit margin

Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
AKTX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$13.8M
Liabilities
$12.0M
Debt to equity
6.72
AKTX's short-term assets ($13.81M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AKTX's short-term assets ($13.81M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AKTX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
AKTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
N/A
Investing
N/A
Financing
N/A
AKTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

AKTX vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
AKTX$26.95M+3.87%N/A15.05x
ENLV$27.14M-7.01%-1.00x0.61x
EQ$27.31M-1.13%-1.55x1.01x
LMNL$26.36M+0.12%86.63x1.62x
EVGN$26.29M+1.78%-1.13x1.84x

Akari Therapeutics Stock FAQ

What is Akari Therapeutics's quote symbol?

(NASDAQ: AKTX) Akari Therapeutics trades on the NASDAQ under the ticker symbol AKTX. Akari Therapeutics stock quotes can also be displayed as NASDAQ: AKTX.

If you're new to stock investing, here's how to buy Akari Therapeutics stock.

What is the 52 week high and low for Akari Therapeutics (NASDAQ: AKTX)?

(NASDAQ: AKTX) Akari Therapeutics's 52-week high was $13.40, and its 52-week low was $2.81. It is currently -72.99% from its 52-week high and 28.92% from its 52-week low.

How much is Akari Therapeutics stock worth today?

(NASDAQ: AKTX) Akari Therapeutics currently has 7,444,917,123 outstanding shares. With Akari Therapeutics stock trading at $3.62 per share, the total value of Akari Therapeutics stock (market capitalization) is $26.95M.

Akari Therapeutics stock was originally listed at a price of $1,600.00 in Jan 6, 2014. If you had invested in Akari Therapeutics stock at $1,600.00, your return over the last 9 years would have been -99.77%, for an annualized return of -49.18% (not including any dividends or dividend reinvestments).

How much is Akari Therapeutics's stock price per share?

(NASDAQ: AKTX) Akari Therapeutics stock price per share is $3.62 today (as of Sep 22, 2023).

What is Akari Therapeutics's Market Cap?

(NASDAQ: AKTX) Akari Therapeutics's market cap is $26.95M, as of Sep 25, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Akari Therapeutics's market cap is calculated by multiplying AKTX's current stock price of $3.62 by AKTX's total outstanding shares of 7,444,917,123.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.